Pharmacy

Top Medical News
Fish oil products do not meet recommended EPA, DHA levels
19 hours ago
Serving sizes of different fish oil products do not usually provide adequate eicosapentaenoic acid (EPA) and docosehexaenoic acid (DHA) intake to deliver cholesterol-lowering benefits, according to a study.
First-line serplulimab + chemo ups survival in extensive-stage SCLC
Roshini Claire Anthony, Yesterday

The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.

ADHD medication use carries no excess risk of cardiovascular diseases
Yesterday
Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.
SG, HK docs delay prescribing clozapine for treatment-resistant schizophrenia
Jairia Dela Cruz, Yesterday
Clinicians in Singapore and Hong Kong appear to delay the initiation of clozapine for treatment-resistant schizophrenia (TRS) despite familiarity with treatment guidelines, as reported in a study.
ENT-01 relieves constipation in patients with Parkinson’s disease
Yesterday
Oral ENT-01 safely and significantly improves constipation in patients with Parkinson’s disease (PD), results of a phase IIb study have shown.
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
Audrey Abella, Yesterday
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.
Rivaroxaban + aspirin combo halves stroke risk in COMPASS
Stephen Padilla, 2 days ago
Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.
Special Reports
Product Highlight - Amnoz
30 Nov 2022
Amlodipine 5 mg and 10 mg tab
Product Highlight - Cruzor
30 Nov 2022
Irbesartan 300 mg FC tab
Product Highlight - Roxatin
30 Nov 2022
Rosuvastatin 10 mg and 20 mg FC tab
FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC
Elaine Soliven, 30 Nov 2022
Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.
Timely treatment of patients at risk for severe COVID-19 prevents severe outcomes
Dr. Asok Kurup, Dr. Alex Soriano, 31 Oct 2022

Despite widespread uptake of vaccinations, COVID-19 remains a serious health issue for high-risk patients, owing to the emergence of new variants of concern (VOCs), waning immunity, and breakthrough infections.

At a recent symposium in Singapore, esteemed experts Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, and Dr Alex Soriano, Head of Infectious Diseases Department, Hospital Clínic of Barcelona and Assistant Professor, University of Barcelona, Spain, gave insights on the evolution of global trends since the start of the COVID-19 pandemic and discussed key challenges in managing high-risk patients with COVID-19 in the ICU. They also highlighted early treatment strategies to minimize the burden of COVID-19 on healthcare systems.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 04 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Product Highlight - Idacio
13 Sep 2022
Adalimumab soln for inj 40 mg/0.8 mL
Conference Reports
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
Audrey Abella, 02 Dec 2022
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.
FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC
Elaine Soliven, 30 Nov 2022
Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Roshini Claire Anthony, 25 Nov 2022

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

Letermovir as good as valganciclovir for CMV prophylaxis
Elaine Soliven, 25 Nov 2022
The novel antiviral letermovir is as good as the current standard of care valganciclovir in preventing cytomegalovirus (CMV) infection in post-kidney transplant patients, but with less toxicity, according to a phase III trial presented at IDWeek 2022.
TB rates elevated after ART initiation in PLHIV
Roshini Claire Anthony, 21 Nov 2022

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

Low use of CVD prevention strategies in people with HIV
Roshini Claire Anthony, 18 Nov 2022

There is an underutilization of cardiovascular disease (CVD) prevention strategies in people living with HIV (PLHIV) who are at risk of CVD, according to a study presented at HIV Glasgow 2022.

Intensive BP-lowering a no-go after reperfusion in ischaemic stroke
Roshini Claire Anthony, 14 Nov 2022

An intensive blood pressure target (<120 mm Hg) should be avoided in patients who have undergone endovascular thrombectomy for acute ischaemic stroke (AIS) for large-vessel occlusion (LVO), results of the phase III ENCHANTED2/MT* trial showed.

Product Highlights
CME Modules